BioCryst (BCRX) Receives a Buy from Wedbush

In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Chico covers the Healthcare sector, focusing on stocks such as Edgewise Therapeutics, Travere Therapeutics, and Climb Bio. According to TipRanks, Chico has an average return of 15.4% and a 54.84% success rate on recommended stocks.

In addition to Wedbush, BioCryst also received a Buy from RBC Capital’s Brian Abrahams in a report issued on July 7. However, today, J.P. Morgan initiated coverage with a Hold rating on BioCryst (NASDAQ: BCRX).

Based on BioCryst’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $156.41 million and a GAAP net loss of $721.81 million. In comparison, last year the company earned a revenue of $145.53 million and had a net profit of $32 thousand

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Most recently, in May 2026, Amy E McKee, a Director at BCRX sold 11,180.00 shares for a total of $100,284.60.